Targeting the telosome: Therapeutic implications by M. Folini et al.
This article appeared in a journal published by Elsevier. The attached
copy is furnished to the author for internal non-commercial research
and education use, including for instruction at the authors institution
and sharing with colleagues.
Other uses, including reproduction and distribution, or selling or
licensing copies, or posting to personal, institutional or third party
websites are prohibited.
In most cases authors are permitted to post their version of the
article (e.g. in Word or Tex form) to their personal website or
institutional repository. Authors requiring further information
regarding Elsevier’s archiving and manuscript policies are
encouraged to visit:
http://www.elsevier.com/copyright
Author's personal copy
Review
Targeting the telosome: Therapeutic implications
Marco Folini, Paolo Gandellini, Nadia Zaffaroni ⁎
Department of Experimental Oncology and Laboratories, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy
a b s t r a c ta r t i c l e i n f o
Article history:
Received 16 December 2008
Received in revised form 28 January 2009
Accepted 30 January 2009
Available online 5 February 2009
Keywords:
Telosome
Telomerase
Telomere
G-quadruplex
Cancer
Since telomere integrity is required to guarantee the unlimited replicative potential of cancer cells,
telomerase, the enzyme responsible for telomere length maintenance in most human tumors, and lately also
telomeres themselves have become extremely attractive targets for new anticancer interventions. At the
current status of knowledge, it is still not possible to deﬁne the best therapeutic target between telomerase
and telomeres. It is noteworthy that interfering with telomeres, through direct targeting of telomeric DNA or
proteins involved in the telosome complex, could negatively affect the proliferative potential not only of
tumors expressing telomerase activity but also of those that maintain their telomeres through alternative
lengthening or still unknown mechanisms. This review presents the different therapeutic approaches
proposed thus far and developed in preclinical tumor models and discusses the perspectives for their use in
the clinical setting.
© 2009 Elsevier B.V. All rights reserved.
1. Introduction
1.1. Telomeres and telomere maintenance mechanisms
Telomeres are heterochromatic structures located at the ends of
chromosomes. In humans, they consist of tandem repeats of the
TTAGGG sequence with a 3′ overhang that plays important structural
and functional roles. Such a 3′ single-stranded telomere overhang can
invade homologous double-stranded telomeric tracts, displace the G-
strand and anneal with the C-strand, thus giving rise to a lasso-like
structure, known as the telomeric loop (t-loop) [1]. Telomeric DNA is
bound by an array of specialized proteins that form a protective
structure known as the telosome [2] or shelterin [3]. Telomeres are
essential to protect chromosome ends (capping function) and
maintain chromosomal stability and genome integrity [1]. In somatic
cells, telomeres shorten with each round of cell division due to the
inability of DNA polymerase to fully replicate the end of chromosomes
[4], and shortened telomeres trigger replicative senescence [5].
A hallmark of cancer cells is their unlimited proliferative potential,
which can be achieved through the activation of a telomere
maintenance mechanism [6]. The main mechanism for telomere
elongation is the enzyme telomerase, a RNA-dependent DNA poly-
merase that adds multiple copies of the TTAGGG motif to the end of
the G-strand of the telomere [7]. The core enzyme consists of an RNA
component (hTR) that provides the template for the de novo synthesis
of telomeric DNA [8] and a catalytic subunit hTERT, which has reverse
transcriptase activity [9].
Recent evidence suggests that the catalytically active telomerase
exists as a complex of two molecules each of hTERT, hTR and dyskerin
[10]. In addition to its role in maintaining chromosome ends through
the regulation of telomere length, telomerase activation has been
recently implicated in providing growth-promoting properties to
tumor cells [11,12]. Telomerase is present in 85–90% of human cancers
[13] but is generally undetectable in somatic cells, with a few
exceptions including stem cells and some highly proliferative cell
types. The complex mechanisms by which telomerase activity is up-
regulated in human tumors are being studied, and the altered
expression of oncogenes and tumor suppressor genes seems to be
involved [14,15].
An alternative mechanism for telomere elongation, the so-called
alternative lengthening of telomeres (ALT, reviewed in 16), is present
in a signiﬁcant proportion of telomerase-negative human tumors of
mesenchymal and neuroepithelial origin [16,17]. Although the
molecular events leading to ALT activation in tumors are almost
completely unknown, there is evidence to suggest that it relies on
homologous recombination events at telomeres. Lack of telomerase
gene expression in ALT tumor cells seems to be associated with
chromatin remodeling at the hTR and hTERT promoters [18]. Themain
features of ALT include long and heterogeneous telomeres and
subnuclear structures termed ALT-associated promyelocytic leukemia
nuclear bodies, which contain telomeric DNA, telomere-binding
proteins and proteins involved in DNA recombination and replication
[16,17].
1.2. The telosome/shelterin complex
Mammalian telomeres are associated with the high-molecular-
weight telosome/shelterin complex, consisting of six interdependent
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telomeric core proteins: telomeric-repeat-binding factor 1 (TRF1) and
2 (TRF2), TRF1-interacting protein 2 (TIN2), transcriptional repressor/
activator protein RAP1, protection of telomeres 1 (POT1) and POT1-
and TIN2-organizing protein (TPP1) [3]. TRF1, TRF2 and POT1 directly
associate to telomeric DNA and are interconnected to each other by
TIN2, RAP1 and TPP1. The telosome/shelterin complex allows
telomeres to exist in two states: a “capped” one in which the 3′
overhang is protected from degradation and inappropriate repair
mechanisms but is not accessible to telomerase, and an “uncapped”
state inwhich telosome proteins are present but leave the 3′ overhang
accessible to telomerase [19].
TRF1, TRF2 and POT1 are essential regulators of telomere structure,
capping and length control. TRF1 and TRF2 speciﬁcally bind to double-
stranded telomeric repeats through a Myb-like helix/turn/helix motif
[20]. TRF1 is a ubiquitously expressed protein that negatively
regulates telomere length by physically preventing telomerase access
to telomere ends [21], whose function is regulated by TIN2 [22]. TRF1
also binds proteins with non-telomeric functions, such as poly(ADP-
ribose) polymerase and tankyrase 1 [23]. Although the precise roles of
tankyrase 1 are not completely understood, it has been shown that the
enzyme can ADP-ribosylate TRF1, thus interfering with its negative
regulation of telomere length [24]. TRF2 plays a key role in the
protection of chromosome ends by stabilizing the 3′ overhang and
contributing to the formation of the t-loop structure at the end of the
telomere [25]. Moreover, it interacts with RAP1 [26] and brings to
telomeres a variety of proteins involved in DNA damage response,
including the Mre11/Rad50/Nbs1 complex, Ku heterodimer and
ataxia-telangiectasia mutated (ATM) kinase [26].
As regards POT1, it has been shown that, following heterodimer-
izationwith TPP1, the protein speciﬁcally binds to and protects single-
stranded telomeric DNA [27]. In addition, the POT1–TPP1 complex
seems to favor the recruitment of telomerase to telomeres, thus
participating in the telomerase-dependent control of telomere length
[28]. However, the function of POT1 in telomere length control is still
controversial, since some evidence points to POT1 as a negative
regulator of telomere length, as a consequence of its ability to prevent
telomerase from gaining access to 3′ telomere ends [3]. It has been
demonstrated that, in association with TRF2, POT1 participates in the
protection of telomeres by contributing to the t-loop formation and by
regulating the nucleolytic processing responsible for the 3′ overhang
formation [29]. In addition, POT1 is interconnected to TRF1 and TRF2
through TIN2 and TPP1 [30]. Evidence has been provided that the
coordinated interaction among TIN2, TPP1 and POT1, not only in the
nucleus but also in the cytoplasm, regulates the assembly and function
of the telosome, which highlights the importance of the spatial control
of telomeric proteins to guarantee the maintenance of telomere
integrity [30].
In addition to the telosome/shelterin complex, mammalian
telomeres interact with other factors (e.g., tankyrase 1 and 2, poly
(ADP-ribose) polymerase, ATM, ATM and Rad3-related (ATR), and
general DNA repair/recombination factors), which altogether coop-
erate to determine telomere replication, protection and stability, thus
contributing to the integrity and dynamics of the ends of chromo-
somes [31].
2. Targeting telomerase and telomeres
2.1. Telomerase inhibitors
Since unlimited proliferative potential has been identiﬁed as one of
the six hallmarks of cancer [6], telomere maintenance mechanisms
have been proposed as potential targets for new anticancer interven-
tions [32]. Due to the selective reactivation of telomerase in most
human tumors, the possibility to interfere with its expression and/or
functions has been actively pursued through the use of different
approaches aimed to i) inhibit the enzyme's catalytic activity; ii)
interfere with the expression of its components (i.e., hTR, hTERT); iii)
affect the signaling pathways responsible for the post-translational
modiﬁcations of the enzyme.
Among the ﬁrst drugs tested for their ability to competitively
inhibit telomerase activity are nucleoside analogs, which act as chain-
terminators during nucleotide polymerization. Several nucleotide
analogs have been proven to efﬁciently inhibit telomerase activity
and cause telomere shortening, depending on the concentration and
duration of exposure [33–37], as well as to induce antiproliferative
and antitumor effects in several tumor models in vitro and in vivo
[38]. A variety of non-nucleoside compounds have also been shown
to inhibit telomerase [37,38], including a mixed-type non-competi-
tive inhibitor, BIBR1532. It binds to a site in the enzyme which is
distinct from those for deoxyribonucleotides and the DNA primer
[39] and is one of the most potent telomerase inhibitors discovered
thus far [38]. The exposure of human cancer cells of different
histological origin to BIBR1532 led to progressive telomere short-
ening and inhibition of cell proliferation, independently of p53 gene
status [37], and to a marked reduction in the tumorigenic potential
following xenotransplantation into nude mice [38]. A dose-depen-
dent cytotoxic activity of the compound was also observed in
leukemia cell lines and primary cultures and was paralleled by time-
dependent individual telomere erosion, loss of TRF2 and increased
phosphorylation of p53 [40]. In addition, pharmacological telomer-
ase inhibition by both nucleoside and non-nucleoside inhibitors has
been shown to sensitize drug-resistant cancer cells to chemother-
apeutic treatments [41].
Antisense-mediated approaches aimed at inhibiting the expres-
sion of telomerase components have been developed through the use
of chemically modiﬁed oligonucleotides (including phosphorothio-
ates, RNA oligomers containing nucleotides with alkyl modiﬁcations
at the 2′ position of the ribose, 2′,5′-oligoadenylate antisense
oligomers, N3′→P5′ phosphoramidates and peptide nucleic acids).
Such oligonucleotides are characterized by pharmacokinetics and
therapeutic properties superior to those of conventional nucleic acid-
based antisense oligomers [32]. Catalytic RNAs such as ribozymes as
well as small interfering RNAs (siRNAs), which are the terminal
effectors of the RNA interference pathway, have been also used as
antisense-based tools [32]. The different antisense strategies explored
thus far to target hTR mainly acted as template antagonists, leading to
cancer cell growth arrest and reduced viability only after several
population doublings as a consequence of the interference with
telomere lengthening activity of the enzyme. Such evidence is in
keeping with the classical mechanism by which telomerase inhibition
induces a delayed cell growth arrest and death as a result of critically
shortened telomeres (“slow pathway”, Fig. 1).
Since such a cellular response has been shown to be largely
dependent on the initial telomere length in a given tumor cell
population [42], single-agent therapies based on inhibitors targeted to
hTR would need long-term treatment to induce effective impairment
of growth of cancer cells with relatively long telomeres. At present, the
most promising oligomer targeting hTR is GRN163L, a lipid palmidate
derivative of the parent thiophosphoramidate GRN163, which
demonstrated in vivo activity against a panel of xenografted tumors
with short telomeres [42–45] and an ability to prevent lung
metastases in animal models [46]. Recent results suggest that the
compound could also act in an hTR-independent fashion. Speciﬁcally,
the potent antimetastatic effect of GRN163L could partially rely on its
anti-adhesive properties independently of binding to hTR [47].
Interestingly, phase I/II clinical trials using GRN163L for the treatment
of chronic lymphocytic leukemia patients and solid tumors have
recently begun.
Several studies have shown that antisense molecules (including
ribozymes, siRNAs and peptide nucleic acids) aimed at down-
regulating hTERT expression are able to induce short-term antipro-
liferative effects and programmed cell death [32,48,49], which cannot
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be explained by the classical model based on telomere shortening.
Interference with hTERT might therefore affect aspects of the control
of cell proliferation other than telomere length (“fast pathway”, Fig.1).
It has been consistently demonstrated that the early antiproliferative
effects caused by hTERT knockdown are the consequence of the
induction of telomere dysfunctions and a DNA damage response at the
telomere level through pathways independent of the telomere-
elongating activity of the enzyme [11,12].
This novel function of telomerase was ﬁrst documented by Cao
et al. [50], who reported that the quickly induced programmed cell
death following hTERT down-regulation in human breast cancer cells
could be counteracted by the ectopic expression of a mutant hTERT
lacking telomerase activity. This ﬁnding has conferred to hTERT a
putative pro-survival and anti-apoptotic function, which is indepen-
dent of telomerase catalytic activity and likely relies on the telomere
capping function of the enzyme [19]. This concept was supported by
our study which showed that exposure of prostate cancer cells to a 2′-
O-methyl-RNA phosphorothioate oligonucleotide targeting hTERT
induced almost complete inhibition of telomerase activity as a
consequence of a marked reduction of the hTERT mRNA expression
level, an early decline of cell growth and apoptotic cell death without
any appreciable telomere shortening [51]. Conversely, exposure of the
same cells to a 2′-O-methyl-RNA phosphorothioate oligonucleotide
targeting the template region of hTR failed to interfere with cell
proliferation in spite of the almost complete abrogation of telomerase
activity [51].
Numerous compounds have also been shown to affect telomerase
via an indirect mechanism. In fact, telomerase regulation is complex
and involves several pathways that provide an impressive number of
“druggable” targets. Speciﬁcally, heat shock protein 90, protein kinase
C, histone deacetylase, COX-2 and tyrosine kinase inhibitors have all
demonstrated an ability to inhibit telomerase activity [38]. Pharma-
cological agents that act on hormonal pathways such as tamoxifen
[52] as well as a number of compounds from various sources,
including nonsteroidal anti-inﬂammatory drugs and anti-oxidants
[38], also negatively interfere with the enzyme's activity. However,
since thesemolecules can affect several cellular targets, it is difﬁcult to
establish to what extent telomerase inhibition is relevant for their
therapeutic activity.
Experimental data show that interference with telomerase
expression and/or function leads to increased sensitivity of cancer
cells to conventional anticancer drugs and radiation [32,38]. Such data
corroborate the notion that telomerase represents a promising
anticancer target also for the design of new combination therapies.
Fig.1. Cellular consequences of telomerase and telosome targeting. Telomerase inhibitors may induce either a delayed antiproliferative effect through a “slow” pathwaymainly based
on telomere erosion (BIBR1532, hTR inhibitors) or a quick antiproliferative effect through a “fast” pathway mainly based on telomere uncapping (hTERT inhibitors). Inhibitors of
telosome proteins and G4 ligands mainly induce telomere uncapping.
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2.2. Interference with telosome proteins
Whereas telomerase inhibitors have been developed with the
purpose to preclinically validate new therapeutic strategies aimed at
inhibiting the growth of tumor cells and enhancing their susceptibility
to drugs, studies carried out to interfere with the expression/function
of telosome components have been mainly devoted to understand
the speciﬁc role they exert in the regulation of telomere structure
and dynamics [4,53,54]. As regards TRF1, long-term overexpression
of the protein in the telomerase-positive HT1080 cell line resulted
in a gradual and progressive telomere shortening, whereas telo-
mere elongation was induced by expression of a dominant-negative
TRF1 mutant that inhibited binding of endogenous TRF1 to
telomeres. As TRF1 did not affect the expression of telomerase, it
has been suggested that the binding of TRF1 controls telomere length
by inhibiting the action of telomerase at the ends of individual
telomeres [21].
Most data on the role of telomere-related proteins have high-
lighted that the telosome acts as a physical cap to protect the ends of
chromosomes from being recognized as natural double-strand breaks,
thereby making it possible to distinguish normal ends from double-
strand breaks and avoiding the activation of DNA damage checkpoints.
The notion that deprotected telomeres activate a DNA damage
response gained support from the evidence that DNA damage
response factors, such as 53BP1, γH2AX, Mre11, and the phosphory-
lated form of ATM, can localize at uncapped telomeres, forming
cytological structures referred to as telomere dysfunction-induced
foci (TIF) [55]. The protective (i.e., capping) function of telosome
proteins has been primarily assigned to TRF2. Inhibition of TRF2
through the overexpression of a dominant-negative mutant of the
protein (TRF2ΔBΔM) – able to heterodimerize with the endogenous
TRF2 and to block its binding to telomeric DNA [56] – caused loss of
the 3′ overhang and resulted in a high frequency of chromosome end-
to-end fusions. Such a response is a consequence of the activation of
DNA ligase IV-dependent nonhomologous end joining and activation
of the ATM kinase/p53 DNA damage response pathway, ultimately
leading to cell death in several in vitro models [3]. Such evidence
indicates TRF2 as an early component of the DNA damage response
system, as also pointed out by the ﬁnding that overexpression of TRF2
decreased the accumulation of γH2AX at photo-induced breaks in
human cells [57].
It has been also demonstrated that mice overexpressing TRF2 in
the skin show critically short telomeres and are susceptible to UV-
induced carcinogenesis as a result of deregulated XPF/ERCC1 activity
[58]. Furthermore, the expression of TRF2 in hTR-null mice led to
chromosome instability, induction of DNA damage and a high
frequency of telomere recombination [58]. The latter evidence has
suggested that increased expression of TRF2, along with telomerase
deﬁciency, can represent an event that could sustain tumorigenesis by
helping to bypass the cell proliferation barrier imposed by short
telomeres through the derepression of the ALT pathway, hence
promoting the growth of tumors with high chromosomal instability
[59]. In addition, mouse models knocked out for TRF2 showed
embryonic lethality, and cells derived from TRF2- and p53-null
embryos were characterized by loss of telomere protection and a
massive increase in end-to-end fusions [59].
It has also been reported that in checkpoint-compromised
telomerase-positive human ﬁbroblasts, TRF2 inhibition promoted
heritable changes that increase the ability to grow in soft agar but not
tumor growth in nude mice. This transforming activity was associated
to telomere instability but was independent of an altered control of
telomere length. Such a ﬁnding supports the idea that telomere
dysfunctionmight contribute to cancer progression even at late stages
of the oncogenesis process, after the telomerase reactivation step [60].
In contrast, combined siRNA-mediated knockdown of TRF2 and
hTR (by using a lentiviral vector bearing a mutant hTR template and a
shRNA targeting hTR) resulted in an additive inhibitory effect on the
growth of melanoma cells, which indicates a function of TRF2 in
sustaining cancer cell proliferation [61]. In addition, RNAi-mediated
inhibition of TRF2 expression partially reversed the resistance
phenotype of the multidrug-resistant variant SGC7901 gastric cancer
cells, thereby suggesting a possible role of TRF2 in drug resistance of
gastric cancer [62].
Dysfunctional telomeres can also be induced by interference with
expression of components of the telosome other thanTRF2. It has been
reported that activated ATM directly phosphorylates Pin2/TRF1 on the
conserved Ser(219)-Gln site in vitro and in vivo and that transfection
of tumor cells with a Pin2 mutant refractory to ATM phosphorylation
on Ser(219) potently induces mitotic entry and apoptosis and
increases radiation hypersensitivity [63]. In contrast, Pin2 mutants
mimicking ATM phosphorylation on Ser(219) completely failed to
induce apoptosis and also to reduce radiation hypersensitivity of A-T
cells. The phenotype of the phosphorylation-mimicking mutants is
the same as that resulting from inhibition of endogenous Pin2/TRF1 in
A-T cells by its dominant-negative mutants [63]. These results
demonstrated that ATM interacts with and phosphorylates Pin2/
TRF1 and suggest that Pin2/TRF1 may be involved in cellular response
to DNA double-strand breaks [63].
It has also been reported that TRF2 cooperates with POT1 to
maintain telomere integrity [64]. The over-expression of exogenous
POT1 blocks the erosive effect on the 3′ overhang and the occurrence
of chromosome abnormalities detectable in different cells expressing
the dominant-negative form of TRF2 [64]. It has been recently
reported that TRF2 and POT1 act independently to repress the ATM-
and ATR-dependent DNA damage responses [65]. In fact, telomere
damage generated by TRF2 loss primarily activated an ATM-
dependent response. Deletion of TRF2 from Atm+/+ cells led to
induction of TIF and phosphorylation of Chk2, whereas such a
response was largely abrogated in Atm−/− mouse cells [65]. In
contrast, the role of POT1 in repressing the activation of ATR kinase at
natural chromosome ends was demonstrated by evidence that TIF
formation in POT1a/b double knockout mouse cells was signiﬁcantly
reduced when ATR was inhibited by using a short hairpin RNA [65].
The role of POT1 in protecting telomeres has been also evaluated in
breast cancer cells exposed to anti-POT1 siRNAs [64]. Speciﬁcally, the
POT1 knockdown resulted in the induction of apoptosis, consequent
to telomere dysfunction, increased expression of p53 and Bax, and
concomitant decrease of Bcl-2 levels, in breast cancer cells [64] and in
a marked increase of TIF in the G1 phase of the cell cycle in HeLa cells
and in primary and hTERT-expressing BJ ﬁbroblasts [29]. In addition,
ﬁbroblasts responded to POT1 depletion with strongly reduced
proliferation and induction of senescence, independently of the
presence of telomerase [29]. A role for POT1 in carcinogenesis has
been further suggested by ﬁndings showing that deletion of the POT1
gene in mice resulted in chromosomal instability and increased
telomere recombination [59].
It has been reported that transient knockdown of TPP1 in mouse
embryonic cells initiates a robust ATR-dependent DNA-damage
response and that its long-term knockdown elicits primarily an
ATM-dependent DNA-damage response. Although the molecular
mechanism contributing to this difference in damage signaling is
not yet clear, biochemical analysis suggests that TPP1 not only binds
POT1, but also interacts with TIN2 to stabilize TRF1–TIN2–TRF2
interaction [66]. In addition, disrupting the nuclear export signal of
TPP1 resulted in a telomeric DNA-damage response and telomere
length deregulation [30].
Depending on the genetic makeup of the cells, dysfunctional
telomeres can lead to the induction of either apoptosis or senescence.
In this context, analysis of the extent to which the cellular level of
telomere dysfunction and p53 gene status affect these cellular
responses in mouse liver has been conducted through TRF2 inhibition
by TRF2ΔBΔM [67]. It has been shown that the level of telomere
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dysfunction correlated with the level of TRF2ΔBΔM protein expression,
resulting in chromosomal fusions, aberrant mitotic ﬁgures and
aneuploidy of mouse liver cells. Such alterations provoked p53-
independent apoptosis but a strictly p53-dependent senescence
response in distinct cell populations. Speciﬁcally, apoptosis was
associated with a higher expression of TRF2ΔBΔM, whereas cellular
senescence was associated with low levels of dominant-negative TRF2
expression, providing evidence that induction of senescence or
apoptosis in vivo depends on the cellular level of telomere dysfunction
and on p53 gene function [67]. Accordingly, it has been demonstrated
that overexpression of dominant-negative mutant TRF2 caused
apoptosis in tumor cells whereas normal ﬁbroblasts went into
senescence [68].
2.3. G-quadruplex stabilization
G-quadruplexes (G4) are a family of nucleic acid secondary
structures stabilized by G quartets (each composed of four guanines,
held together by a cyclic arrangement of 8 hydrogen bonds), which
form in the presence of cations and are thought to play a role in key
biological processes. The in vivo existence of G4 in oncogene
promoters and telomeres has been demonstrated through the use of
speciﬁc ligands [69,70]. The human telomeric G-overhang can fold
into several different intramolecular quadruplex structures that differ
for the position of the adjacent loop regions. The crystal and solution
structures of G4 formed by human telomeres have recently been
elucidated, and this is boosting the rational development of novel
effective compounds [38]. The number of known G4 ligands has
grown rapidly over the past few years (reviewed in 38). All of them
target G4 structures by a reversible process, whereas no selective
irreversible G4 alkylator has been thus far described. Features shared
by many of these ligands include a large ﬂat aromatic surface, the
presence of cationic charges, and the ability to adopt a terminal
stacking mode.
Due to the inability of telomerase to extend a G4-folded telomeric
substrate, G4-interacting agents were ﬁrst evaluated as telomerase
inhibitors. In agreement with the initial paradigm for telomerase
inhibition, long-term exposure of human cancer cells with subtoxic
doses of some G4 ligands (such as disubstituted triazines and
telomestatin) induced progressive telomere shortening and replica-
tive senescence [71–74]. However, in several other studies, it was
shown that G4 ligands, including BRACO 19 and RHPS4, were able to
cause a short-term antiproliferative response (mainly in terms of
induction of apoptosis) that cannot be simply explained by telomerase
inhibition. Speciﬁcally, the observation that BRACO 19 and other G4
ligands caused chromosome end-to-end fusions, telophase bridges,
together with the appearance of p16-associated senescence, led to the
proposal that the target of G4 ligands is the telomere rather than
telomerase [75,76].
G4-stabilizing agents were also shown to inhibit the growth of ALT
cell lines. Speciﬁcally, the quinoline-based G4-ligands 115405 and
RHPS4 were both able to cause growth inhibitory effects in the SV40-
immortalized human ﬁbroblast cell line GM847 that expresses the ALT
phenotype [71, 77]. In addition, 2,6-pyridine-dicarboxamide deriva-
tives, displaying strong selectivity for the G4 structures, were found to
induce antiproliferative effects in the telomerase-negative human
osteogenic sarcoma cell line Saos-2, which maintains its telomeres
through ALT mechanisms [78]. These ﬁndings further corroborated
the hypothesis that the antiproliferative effect of G4 ligands was
largely independent of the presence of active telomerase [75,77]. In
accord with this hypothesis, it has also been reported that G4 ligand-
induced dysfunction at the level of telomeres (which under normal
conditions prevent the recognition of natural chromosome ends as
double-strand breaks) provokes a DNA-damage response in human
tumor cells, as evidenced by the formation of γH2AX foci that partially
co-localize at the telomere.
Telomestatin also induces degradation of the G-overhang and a
reduction of telomeric repeat fragment, with a concomitant displace-
ment of POT1 and TRF2 from their telomere sites in cancer but not in
normal cells [79,80]. Based on this evidence, a consistent mechanism
of action schema is now emerging for G4 ligands in tumor cells, which
initially involves alteration of the G-overhang structure followed by
degradation through a DNA-damage repair pathway and release of
POT1 from telomeres. In addition, G-overhang degradation induces a
further t-loop instability followed by anaphase bridges and telomere
loss associated with TRF2 release from telomeres [38].
Evidence that G4 ligands selectively limit the growth of cancer cells
without affecting the viability of normal cells [80], together with their
ability to exert an antitumor activity against a variety of human tumor
xenografts (including some inherently resistant to chemotherapy)
and to inhibit the development of metastases in selected in vivo
models [81], provide compelling rationale for the clinical use of these
compounds to target the limitless replicative potential of malignant
cells for broad-spectrum cancer therapy. In addition, very recent data
showing the good pharmacodynamic proﬁle of RHPS4 and its ability
to potentiate the antitumor activity of cytotoxic agents widely used in
cancer treatment, such as taxanes [82] and camptothecins [81],
strongly suggest this drug as a promising anticancer agent.
However, notwithstanding the promising results obtained in
preclinical models, G4 ligands have not yet reached the clinical
setting. One main reason is likely related to the fact that the exact
structure(s) of human telomeric G4 is still controversial. It has been
shown that telomeric G-overhang can fold into several intramolecular
quadruplex structures that differ by the position of the adjacent loop
regions [83]. The knowledge of the intact human G4 structures formed
in vivo under physiological conditions is a prerequisite for structure-
based rational design of compounds able to exert a clinical activity. In
this context, it has been experimentally demonstrated that different
conformations of G4 play a pivotal role in molecular recognition and
govern G4 binding to small molecules. For example, it has been
reported that the G4 ligand TMPyP4 shows preferential binding to the
parallel G4 over its antiparallel counterpart [84].
3. Conclusions and perspectives
Data obtained from preclinical studies on the effects of telomerase
inhibition, accomplished through genetic and pharmacological
approaches, provide a compelling argument to indicate that the
enzyme is a well-validated target for cancer therapy. It emerged that
telomerase inhibition mainly leads to tumor growth impairment
through a slow pathway mediated by progressive telomere erosion,
even though it has been shown that direct targeting of hTERT
expression is able to induce a fast antiproliferative response that relies
on telomere uncapping (Fig. 1). The differences in telomerase
expression, telomere length and predicted stem cell kinetics in
normal versus tumor tissues suggest that no major safety concerns
should be expected with the clinical use of anti-telomerase therapies.
At present, the only telomerase inhibitor in the clinic is GRN163L,
which is currently used in phase I/II trials as a single agent for the
treatment of chronic lymphocytic leukemia and solid tumors. In
addition, based on preclinical evidence suggesting a chemosensitiz-
ing effect of telomerase inhibition, the drug is also used in
combination with paclitaxel and carboplatin for the treatment of
non-small cell lung cancer patients [85]. Another important clinical
application that could be envisaged for GRN163L (as well as for other
compounds able to inhibit telomerase and/or induce telomere
dysfunction) is in combination with radiation therapy. In this context,
it has been recently demonstrated that in the MDA-MB-231 human
breast cancer cells, exposure to GRN163L resulted in progressive
telomere shortening and signiﬁcantly enhanced radiation sensitivity
in vitro and in vivo, likely as a consequence of an impairment in
radiation damage repair [86]. An issue that needs to be addressed for
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the clinical use of telomerase inhibitors is related to the choice of the
best patient population. In this context, the recent ﬁnding that a
signiﬁcant fraction of solid tumors of mesenchymal and neuroe-
pithelial origin expresses the ALT phenotype instead of telomerase
[87,88], and as a consequence is not likely to be affected by
telomerase inhibitors, suggests that telomere maintenance mechan-
ism status should be determined in individual patients before
starting an anti-telomerase treatment. Finally, as for all mechanism-
based therapies, the validation of pharmacodynamic markers of
clinical activity is warranted.
At the preclinical level, it has been demonstrated that the use of
compounds that selectively target components of the telosome
complex or specialized telomere structures, such as G4, can quickly
induce programmed cell death and activate a DNA-damage response
in a variety of tumor models (Fig. 1). In addition, biochemical
determinants of DNA-damage response (i.e., phosphorylation of
H2AX) have been proposed as surrogate markers of tumor response
to be used in clinical trials. Interestingly, some of these compounds
were able to induce antiproliferative effects also in ALT cells, and one
of them, telomestatin, was shown to selectively induce early cell death
in cancer cells, with normal cells remaining viable much longer. Also
widely debatable, it cannot be excluded that protein composition at
the telomere may differ, quantitatively and/or qualitatively, in normal
versus tumor cells and that normal cells may have a higher degree of
telomere stability.
Although a comprehensive survey of telomere-related proteins in
normal and cancer cells has not yet been done, initial evidence
suggests that an altered expression of telomeric protein could be
involved in the development of a malignant phenotype. In this
context, a gradual increase in the expression of TRF1, TRF2, and TIN2
was detected according to the progression of hepatocarcinogenesis,
with a marked increase, paralleled by inversely correlated telomere
lengths, in hepatocellular carcinoma compared to high-grade dys-
plastic nodules [89].
Again, genes encoding for telomere-associated proteins have been
reported to display different patterns of expression in human breast
cancer specimens and in normal breast tissues, suggesting different
and sometimes opposing roles in mammary carcinogenesis [90].
Speciﬁcally, POT1 transcription levels demonstrated a compelling
trend to be lower in malignant tissues and much lower in those
patients who develop recurrent disease, indicating that POT1 may act
as a tumor-suppressor gene [90].
It has been reported that subsets of tumors of different histological
origin, including liposarcoma, osteogenic sarcoma, peritoneal
mesothelioma and glioblastoma multiforme [87,88,91,92], possess
no apparent telomere maintenance mechanism (telomerase or ALT),
revealing that these tumors probably use a mechanism that has not
yet been identiﬁed. However, even though it cannot be excluded that
the presence of a constitutively active telomere maintenance
mechanism is not a stringent requirement for this small fraction of
tumors, it is possible to hypothesize that a therapeutic interference
with telomere homeostasis through the use of telosome/telomere-
interacting agents could negatively affect cell proliferation also in
these malignancies.
Although several small molecules have been demonstrated to exert
at a preclinical level a strong antiproliferative and antitumor effect, as
a result of the direct interference with telomeres (mainly through G4
stabilization), none of these compounds is under clinical develop-
ment. This observation poses a signiﬁcant question concerning the
reliability of the preclinical models that are currently used to evaluate
the therapeutic potential of these compounds. It suggests that more
sophisticated human models (including three-dimensional and
organotypic cultures as well as animal models that address the
problems of tumor heterogeneity and slow replication of tumor stem
cells) should be used to obtain amore realistic proof of the potential of
the proposed therapeutic approach.
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